DUBLIN--(BUSINESS WIRE)--Sep 6, 2019--

The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 report provides a detailed understanding and analysis of how, why and what terms companies enter preclinical stage partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.

Understanding the flexibility of a prospective partner's negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

This report contains a comprehensive listing of over 1,200 preclinical stage partnering deals announced since 2014 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.

Report Scope

Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2014-2019 includes:

  • Trends in preclinical stage dealmaking in the biopharma industry since 2014
  • Analysis of preclinical stage deal structure
  • Access to headline, upfront, milestone and royalty data
  • Case studies of real-life preclinical stage deals
  • Access to over 1,200 preclinical stage deals
  • The leading preclinical stage deals by value since 2014
  • Most active preclinical stage dealmakers since 2014
  • The leading preclinical stage partnering resources

Available contracts are listed by:

  • Company A-Z
  • Headline value
  • Stage of development at signing
  • Deal type
  • Specific therapy target

Analyzing actual contract agreements allows assessment of the following:

  • What are the precise rights granted or optioned?
  • What is actually granted by the agreement to the partner company?
  • What exclusivity is granted?
  • What is the payment structure for the deal?
  • How are sales and payments audited?
  • What is the deal term?
  • How are the key terms of the agreement defined?
  • How are IPRs handled and owned?
  • Who is responsible for commercialization?
  • Who is responsible for development, supply, and manufacture?
  • How is confidentiality and publication managed?
  • How are disputes to be resolved?
  • Under what conditions can the deal be terminated?
  • What happens when there is a change of ownership?
  • What sublicensing and subcontracting provisions have been agreed?
  • Which boilerplate clauses does the company insist upon?
  • Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
  • Which jurisdiction does the company insist upon for agreement law?

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Why do companies partner preclinical stage compounds?

2.1. Introduction

2.2. The role of preclinical stage partnering

2.2.1. In-licensing at preclinical stage

2.2.2. Out-licensing at preclinical stage

2.3. Difference between discovery, preclinical and clinical stage deals

2.4. Reasons for entering into preclinical stage partnering deals

2.4.1. Licensors reasons for entering preclinical stage deals

2.4.2. Licensees reasons for entering preclinical stage deals

2.5. The future of preclinical stage partnering deals

Chapter 3 - Preclinical stage deal strategies and structure

3.1. Introduction

3.2. At what stage do companies partner?

3.2.1. Partnering early in pharmaceutical / biotech Discovery and preclinical stage partnering case studies Case study: LEO Pharma - 4SC Case study: Heptares Therapeutics - Cubist Case study: Incyte - Agenus Bio Case study: Janssen Pharmaceutical - Evotec

3.2.2. Partnering later in pharmaceutical/biotech Clinical stage partnering case studies Case study: Servier - GeNeuro Case study: Teva - Xenon Pharmaceuticals Case study: AstraZeneca - Ardelyx Case study: Baxter - Onconova Therapeutics

3.3. Early and later stage partnering - a risk/cost comparison

3.4. What do companies spend on preclinical stage partnering?

3.5. Pure versus multi-component partnering deals

3.6. Pure licensing agreement structure

3.6.1. Example pure preclinical stage licensing agreements

3.6.1.a. Case study : Merck and Co. - Tesaro

3.6.1.b. Case study : Marina Biotech - Mirna Therapeutics

3.7. Multicomponent preclinical stage partnering agreements

3.7.1. Example multicomponent preclinical stage clauses

3.7.1.a. Case study: Eleven Biotherapeutics - ThromboGenics

3.7.1.b. Case study: Pfizer - InSite Vision

Chapter 4 - Preclinical stage partnering payment strategies

4.1. Introduction

4.2. Preclinical stage payment strategies

4.3. Payment options

4.3.1. Headline values

4.3.2. Upfront payments Conditionality of upfront payments

4.3.3. Loans

4.3.4. Convertible loans

4.3.5. Equity

4.3.6. R&D funding

4.3.7. Licensing fees

4.3.8. Milestone payments

4.3.9. Royalty payments Issues affecting royalty rates Royalties on combination products Case study: Scripps Research Institute-Cyanotech Guaranteed minimum/maximum annual payments Royalty stacking Royalties and supply/purchase contracts

4.3.10. Quids

4.3.11. Option payments

Chapter 5 - Trends in preclinical stage deal making

5.1. Introduction

5.2. Preclinical stage partnering over the years

5.2.1. Attributes of preclinical deals

5.3. Preclinical stage partnering by deal type

5.4. Preclinical stage partnering by disease type

5.5. Partnering by preclinical stage technology type

5.6. Preclinical stage partnering by most active company since 2014

Chapter 6 - Payment terms for preclinical stage partnering

6.1. Introduction

6.2. Guidelines for preclinical stage payment terms

6.2.1. Upfront payments

6.2.2. Milestone payments

6.2.3. Royalty payments

6.3. Preclinical stage payment terms - deal data analysis

6.3.1. Public data

6.3.2. Survey data

6.4. Payment terms analysis

6.4.1. Preclinical stage headline values

6.4.2. Preclinical stage deal upfront payments

6.4.3. Preclinical stage deal milestone payments

6.4.4. Preclinical stage royalty rates

Chapter 7 - Leading preclinical stage deals

7.1. Introduction

7.2. Top preclinical stage deals by value

Chapter 8 - Top 25 most active preclinical stage dealmakers

8.1. Introduction

8.2. Top 25 most active preclinical stage dealmakers

Chapter 9 - Preclinical stage partnering contracts directory

9.1. Introduction

9.2. Preclinical stage deals with contracts 2014 to 2019

Chapter 10 - Preclinical stage deal making by development stage

10.1. Introduction

10.2. Deals by preclinical stage


Appendix 1 - Preclinical stage dealmaking by companies A-Z

Appendix 2 - Preclinical stage dealmaking by industry sector

Appendix 3 - Preclinical stage dealmaking by stage of development

Appendix 4 - Preclinical stage dealmaking by therapy area

Appendix 5 - Preclinical stage dealmaking by technology type

For more information about this report visit https://www.researchandmarkets.com/r/hk25qt

Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900



SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 09/06/2019 10:36 AM/DISC: 09/06/2019 10:36 AM

Copyright Business Wire 2019.